Y型聚乙二醇干扰素琢-2b注射液治疗HCV基因2/3型慢性丙型肝炎患者疗效和安全性的多中心随机对照试验研究

目的以标准剂量的聚乙二醇干扰素(Peg IFN)α-2a联合利巴韦林作为阳性对照,评价新型试验药物Y型Peg IFNα-2b注射液联合利巴韦林治疗2型/3型慢性丙型肝炎(CHC)患者的疗效和安全性。方法采用多中心、随机开放、阳性药对照的Ⅲ期临床试验,筛选符合要求的2型/3型CHC患者,按照2:1的比例随机分配到Y型Peg IFNα-2b组和Peg IFNα-2a组,同时口服利巴韦林,疗程24 w,停药随访24 w。采用Abbott Real Time HCV Genotype II检测HCV基因型,采用Cobas Taq Man实时定量PCR法检测血清HCV RNA水平。详细记录不良事件。主要疗效指标为持续病毒学应答(SVR),并进行非劣效检验。结果本试验实际入组2型/3型CHC患者255例,实际治疗241例。全分析集(FAS)数据显示,158例试验组和83例对照组患者SVR分别为85.4%(95%CI 79.94%~90.94%)和79.5%(95%CI 70.84%~88.20%,P=0.2402);对符合方案分析集(PPS)人群分析显示,试验组和对照组患者SVR分别为87.9%(95%CI 82.45%~93.27%)和85.9%(95%CI 77.82%~94.01%,P=0.7060),率差的95%可置信区间均符合非劣效标准;对PPS人群分析显示,85.8%受试者获得了早期病毒学应答(RVR),RVR的阳性预测值为90.1%;试验组和对照组不良事件发生率相似,分别为95.6%和95.2%,严重不良事件发生率分别为3.8%和3.6%。结论应用Peg IFNα联合利巴韦林治疗2型/3型CHC患者,新型试验药物Y型Peg IFNα-2b具有与对照药物Peg IFNα-2a相似的疗效和安全性。国家科技部“十二五”重大专项(编号:2012ZX10002-003)；“重大新药创制”十二五科技重大专项(编号:2012ZX09303019)

稀疏分光网络中的组播路由机制研究

仅部分节点具有组播能力的光网络称为稀疏分光网络,基于网络性能和成本的考虑,网络常为稀疏分光配置。稀疏分光网络中组播路由主要解决如何为多点传送的组播业务请求寻找合适的光树或光森林的问题。在综合分类的基础上,文章重点对目前稀疏分光网络中的组播路由机制和相关算法进行分析和总结,并对未来工作进行了展望

Ultrasound-assisted synthesis and characterization of isoquinoline-based ionic liquids(超声辅助的异喹啉-离子液体的合成和表征)

为解决传统加热法合成异喹啉-离子液体存在的问题，开发了一种超声辅助合成异喹啉-离子液体的方法。通过异喹啉季铵化过程的对比研究，证明了该方法具有环保性强、产率高、反应时间短等优点。将其扩展至阴离子交换反应，发现超声辐射法有效促进了异喹啉溴化物与简单阴离子［N（CF3SO2）2］−和［PF6］−，以及与复杂阴离子2，4-二氯苯氧乙酸的阴离子交换反应。对所得到的异喹啉-离子液体进行了结构表征以及热行为和溶解度的研究和讨论。结果表明，所得液体具有良好的热稳定性，为快速、高效建立绿色多功能化离子液体库奠定了基础

46.7MeV/u~(12)C引起的弹核碎裂反应

测量了46.7MeV/u~(12)C束流轰击不同靶核的核反应中前方向出射的类弹碎片,发现弹核碎裂产物的最可几能量可用Abrasion图象来解释。它们的平行动量分布宽度满足Goldhaber关系式,实验中提取的约化平行动量分布宽度σ_0=80±10MeV/c,接近于相对论情形下的值,并且σ_0对于不同的反应系统有相近的值

46.7MeV/u~(12)C引起的核反应中碎裂与转移的竞争

本文讨论了46.7MeV/u~(12)C引起的核反应中弹核碎裂与转移反应的共存及相互竞争,实验中提取的转移部分的约化平行动量分布宽度为44±10MeV/c,这比弹核碎裂部分的σ_0=80±10MeV/c要窄。弹核碎裂及转移反应发生的几率都与被转移结团的结构有关

46.7MeV/u~(12)C+~(58)Ni反应中的轻带电粒子关联测量

本文报道了在~(12)C(46.7 MeV/u)+~(58)Ni实验中利用9单元CsI(T1)阵列探测器测量轻带电粒子关联函数的实验结果,详细讨论了关联函数的定义及从实验上提取关联函数的方法。本文还讨论了非稳态粒子衰变在关联粒子测量中的表现,并给出了对于~(58)Ni靶得到的各种粒子组合的关联函数

Preparation of decellularized and crosslinked artery patch for vascular tissue-engineering application

There is an urgent clinical need of tissue-engineering (TE) vascular grafts, so this study was for developing a fast and simple way of producing TE vascular scaffold. The TE vascular scaffold was prepared with pepsin, DNase and RNase enzymatic decellularization and crosslinked with 0.1, 1, 5% glutaraldehyde (GA), respectively. The samples were underwent analyses of burst pressure; suture strength; cytotoxicity; enzymatic degradation in vitro; degradation in vivo; rehydration; biocompatibilities detected with hematoxylin and eosin (H&E), scan electron microscope, immunohistochemistry both in vivo and in vitro; macrophage infiltration and calcification using Von Kossa staining. After being decellularized the scaffold had a complete removal of cellular components, an intact collagen structure. The burst pressure and suture strength were similar to native artery. 0.1% GA crosslinked scaffold showed less cytotoxicity than 1 and 5% GA groups (P < 0.05) and was resistance to enzymatic degradation in vitro. Once being implanted, 0.1% GA group was resistant to degradation and formed endothelium, smooth muscle and adventitia with few macrophages infiltration. However, there appeared calcification in implants compared with that in native artery. This study demonstrated that DVPs producing methods by enzymatic decellularizing and cross-linking with 0.1% GA could be used for clinical TE vascular graft manufacture